Elicera Therapeutics AB (publ) (ELIC.ST)
Elicera Therapeutics AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Gothenburg, VG, SE. The stock last traded at $2.71, down 0.73% on the session, giving a market capitalisation of $181.2M. Its beta of 0.29 implies it has historically moved less than the broad market.
Elicera Therapeutics AB (publ), a Swedish immuno-oncology firm founded in Göteborg in 2014, is dedicated to the clinical development of cell and gene therapies that harness the immune system to combat cancer. Its promising pipeline features several drug candidates, including ELC-100, which is currently undergoing Phase I/II trials for neuroendocrine tumors. The company is also advancing ELC-201 and ELC-401 through preclinical development, with ELC-401 specifically targeting glioblastoma multiforme (a form of brain tumor). Furthermore, Elicera is developing ELC-301, a CAR T-cell therapy intended for the treatment of Non-Hodgkin's B-cell lymphoma. A cornerstone of their work is the iTANK technology platform, engineered to enhance the efficacy of their CAR T-cell therapies and stimulate killer T-cells to attack cancerous cells.
Elicera Therapeutics AB (publ) is most often compared with the following Healthcare names: